TEMPEST THERAPEUTICS INC (TPST)
US87978U1088 - Common Stock
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Friday's session: gap up and gap down stocks
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised...
Top movers in Monday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023
TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tempest Therapeutics (NASDAQ:TPST) just reported results for the fourth quarter...
Tempest Reports Year End 2023 Financial Results and Provides Business Update
Tempest Reports Year End 2023 Financial Results and Provides Business Update
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard...
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...
“Market Mavericks: Stocks Creating Ripples of Success” CLNV, TPST, HNRC, INPX
Intelligent Bio (NASDAQ: INBS) Surges Massively Among Stocks Making BUZZ:TPST, HNST, LTRN, VTAK
Tempest Therapeutics stock rallies in wake of business update (TPST)
Tempest Therapeutics' (TPST) stock rallied after the biotech company said it had extended its cash runway into 2025 and was in talks with potential partners. Read more here.
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC studyNew capital strengthens...